Announcements
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 2.10 |
Offer | -- |
Previous close | 8.76 |
Average volume | -- |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 42.44m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 17 2019.
More ▼